"Scleroderma, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Descriptor ID |
D012595
|
| MeSH Number(s) |
C17.300.799 C17.800.784
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Scleroderma, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Scleroderma, Systemic".
This graph shows the total number of publications written about "Scleroderma, Systemic" by people in this website by year, and whether "Scleroderma, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 1 | 4 |
| 1995 | 4 | 0 | 4 |
| 1996 | 4 | 0 | 4 |
| 1997 | 3 | 1 | 4 |
| 1998 | 3 | 0 | 3 |
| 1999 | 5 | 0 | 5 |
| 2000 | 2 | 0 | 2 |
| 2001 | 6 | 1 | 7 |
| 2002 | 2 | 0 | 2 |
| 2003 | 7 | 0 | 7 |
| 2004 | 8 | 1 | 9 |
| 2005 | 12 | 1 | 13 |
| 2006 | 5 | 0 | 5 |
| 2007 | 12 | 1 | 13 |
| 2008 | 12 | 0 | 12 |
| 2009 | 7 | 2 | 9 |
| 2010 | 11 | 1 | 12 |
| 2011 | 13 | 1 | 14 |
| 2012 | 9 | 1 | 10 |
| 2013 | 14 | 1 | 15 |
| 2014 | 13 | 1 | 14 |
| 2015 | 5 | 1 | 6 |
| 2016 | 10 | 1 | 11 |
| 2017 | 10 | 0 | 10 |
| 2018 | 6 | 1 | 7 |
| 2019 | 7 | 2 | 9 |
| 2020 | 5 | 1 | 6 |
| 2021 | 13 | 0 | 13 |
| 2023 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Scleroderma, Systemic" by people in Profiles.
-
Reduced Cathepsin L expression and secretion into the extracellular milieu contribute to lung fibrosis in systemic sclerosis. Rheumatology (Oxford). 2023 03 01; 62(3):1306-1316.
-
Distinct genome-wide DNA methylation and gene expression signatures in classical monocytes from African American patients with systemic sclerosis. Clin Epigenetics. 2023 02 17; 15(1):25.
-
First Characterization of the Transcriptome of Lung Fibroblasts of SSc Patients and Healthy Donors of African Ancestry. Int J Mol Sci. 2023 Feb 11; 24(4).
-
The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis. Int J Mol Sci. 2023 Feb 03; 24(3).
-
Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis. Arthritis Rheumatol. 2023 03; 75(3):438-448.
-
PDGF Promotes Dermal Fibroblast Activation via a Novel Mechanism Mediated by Signaling Through MCHR1. Front Immunol. 2021; 12:745308.
-
Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. Int J Rheum Dis. 2022 Feb; 25(2):163-174.
-
Antifibrotic factor KLF4 is repressed by the miR-10/TFAP2A/TBX5 axis in dermal fibroblasts: insights from twins discordant for systemic sclerosis. Ann Rheum Dis. 2022 02; 81(2):268-277.
-
A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Pract Res Clin Rheumatol. 2021 09; 35(3):101707.
-
Elevated Fibronectin Levels in Profibrotic CD14+ Monocytes and CD14+ Macrophages in Systemic Sclerosis. Front Immunol. 2021; 12:642891.